WST · 10-Q · 2026Q3 · Full report

Acquisition / Partnership / Divestiture

WEST PHARMACEUTICAL SERVICES INC · 2026-10-29 · Importance 59 · Surprise 60 · Matches filing data

On July 1, 2026, West sold its SmartDose® 3.5mL On-Body Delivery System product line to AbbVie, reducing third-quarter sales by $18.0 million compared with the prior-year quarter. The sale of the assets generated a $55.7 million net gain in the three and nine months ended September 30, 2026, and the agreement also covered associated facilities. West recorded a one-time $22.4 million tax cost associated with the gain and reported proceeds from the asset and facility sale as a factor reducing investing cash outflow. The company also recorded $3.6 million of third-quarter and $9.7 million of nine-month SG&A professional services related to the sale and other M&A activities.

Key facts

• WEST PHARMACEUTICAL SERVICES INC recorded a $55.7 million net gain on the sale of SmartDose® 3.5mL On-Body Delivery System assets for the three and nine months ended September 30, 2026. source
• WEST PHARMACEUTICAL SERVICES INC’s net cash used in investing activities decreased $202.8 million for the nine months ended September 30, 2026, primarily due to SmartDose® 3.5mL asset-sale proceeds to AbbVie and reduced capital expenditures. source
• WEST PHARMACEUTICAL SERVICES INC recorded a pre-tax benefit of $54.0 million and $45.7 million for the three and nine months ended September 30, 2026, respectively, related to M&A activities, primarily its agreement to sell SmartDose® 3.5mL and associated facilities to AbbVie. source
• West depends on third-party suppliers and partners, including single-source suppliers of critical materials and products and its Japanese partner and affiliate, Daikyo. source
• Effective in the first quarter of 2026, WEST PHARMACEUTICAL SERVICES INC renamed its Contract-Manufactured Products reportable segment to West Vantage™; segment composition and previously reported segment financial information were unchanged. source

Impact estimates